Long Dingpei, Alghoul Zahra, Sung Junsik, Yang Chunhua, Merlin Didier
Digestive Disease Research Group, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA.
Department of Chemistry, Georgia State University, Atlanta, GA 30303, USA.
Pharmaceutics. 2023 Sep 16;15(9):2331. doi: 10.3390/pharmaceutics15092331.
Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn's disease, is known to increase the risk of colitis-associated cancer (CAC). CAC has been found to be unresponsive to standard chemotherapy regimens, and the current treatments do not utilize effective small-molecule drugs and colon-targeted delivery systems. Previous studies indicated that the M13-nano-liposome (NL) formulation can effectively target the colon and reshape the gut microbiota in ex vivo cultures, generating altered microbial metabolites that can efficiently prevent chronic UC. In this study, we tested the cancer cell uptake ability of the NL formulation and investigated the potential of the M13-NL formulation to prevent CAC in the azoxymethane (AOM)-exposed IL10 mouse model. Our findings demonstrate that oral administration of M13-NL prevents tumor development in AOM-exposed IL10 mice, suggesting that M13-NL is a promising oral drug formulation for preventing CAC.
炎症性肠病（IBD）包括溃疡性结肠炎（UC）和克罗恩病，已知会增加结肠炎相关癌症（CAC）的风险。已发现CAC对标准化疗方案无反应，并且目前的治疗方法未使用有效的小分子药物和结肠靶向递送系统。先前的研究表明，M13纳米脂质体（NL）制剂可以有效地靶向结肠，并在体外培养中重塑肠道微生物群，产生能够有效预防慢性UC的改变的微生物代谢产物。在本研究中，我们测试了NL制剂的癌细胞摄取能力，并研究了M13-NL制剂在暴露于氧化偶氮甲烷（AOM）的IL10小鼠模型中预防CAC的潜力。我们的研究结果表明，口服M13-NL可预防暴露于AOM的IL10小鼠的肿瘤发生，这表明M13-NL是一种有前景的预防CAC的口服药物制剂。
